View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Cardiff Oncology to Participate in Three Upcoming Investor Conferences...

Cardiff Oncology to Participate in Three Upcoming Investor Conferences  SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.   TD Cowen 46th Annual Health Care ConferenceDate: 03/04/26 Barclays 28th Annual Global Healthcare ConferenceDate: 03/10/26 Leerink Partners Global Healthcare Conference 2026Date: 03/11/26 Interested part...

 PRESS RELEASE

Oxford Square Capital Corp. Schedules Fourth Quarter 2025 Earnings Rel...

Oxford Square Capital Corp. Schedules Fourth Quarter 2025 Earnings Release and Conference Call for March 3, 2026 GREENWICH, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oxford Square Capital Corp. (NasdaqGS: ) (NasdaqGS: OXSQG) (NasdaqGS: OXSQH) announced today that it will hold a conference call to discuss fourth quarter 2025 earnings on Tuesday, March 3, 2026 at 9:00 AM Eastern time. The toll free dial-in number is 1-800-715-9871, access code number 4928384. There will be a recorded replay of the call available for 30 days after the call. If you are interested in hearing the recording, plea...

 PRESS RELEASE

Cardiff Oncology Reports Full Year 2025 Results and Provides Business ...

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p

 PRESS RELEASE

American Coastal Insurance Corporation Announces the Appointment of Tr...

American Coastal Insurance Corporation Announces the Appointment of Troy Crawford as Chief Underwriting Officer ST. PETERSBURG, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- American Coastal Insurance Corporation (Nasdaq Ticker: ACIC) (“the Company”, “American Coastal” or “ACIC”), the insurance holding company of American Coastal Insurance Company (“AmCoastal”), announced today that Troy Crawford, MBA, CPCU, CLU, was appointed as Chief Underwriting Officer of ACIC. Crawford was appointed as Chief Underwriting Officer of AmCoastal in January 2025, overseeing underwriting strategy, risk selectio...

 PRESS RELEASE

American Coastal Insurance Corporation Reports Financial Results for I...

American Coastal Insurance Corporation Reports Financial Results for Its Fourth Quarter and Year Ended December 31, 2025 Company to Host Quarterly Conference Call at 5:00 P.M. ET on February 19, 2026The information in this press release should be read in conjunction with an earnings presentation that is available on the Company's website at . ST. PETERSBURG, Fla., Feb. 19, 2026 (GLOBE NEWSWIRE) -- February 19, 2026: American Coastal Insurance Corporation (Nasdaq: ACIC) ("ACIC" or the "Company"), a property and casualty insurance holding company, today reported its financial results for ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

 PRESS RELEASE

Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare ...

Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25-26, 2026. Details of the presentation can be found below. Presenter: Mani Mohindru, PhD (...

 PRESS RELEASE

American Coastal Insurance Corporation Schedules Fourth Quarter and Fu...

American Coastal Insurance Corporation Schedules Fourth Quarter and Full Year 2025 Financial Results and Conference Call ST. PETERSBURG, Fla., Feb. 09, 2026 (GLOBE NEWSWIRE) -- American Coastal Insurance Corporation (Nasdaq Ticker: ACIC) (“the Company”, “American Coastal” or “ACIC”), the insurance holding company of American Coastal Insurance Company (“AmCoastal”), announced today that it expects to release its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 19, 2026, after the close of the market, and will conduct its quarterly confer...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 31, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Cardiff Oncology Announces Positive Update from its Randomized Phase 2...

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – - Data support selection of 30 mg onvansertib dose for registrational program in first-line RAS-mutated mCRC – - Data validate previously reported positive results from Phase 2 trial of onvansertib with FOLFIRI/bev in second-line mCRC bev-naï...

 PRESS RELEASE

Cardiff Oncology Announces Executive Leadership Changes as it Transiti...

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company’s next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology’s Board of Directors since 2021 and a seasoned b...

Metropolitan Bank Holding Corp: 1 director

A director at Metropolitan Bank Holding Corp sold/sold after exercising options 14,445 shares at 92.284USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the compan...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 24, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 17, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 10, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 9, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 6, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored T...

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in chronic myelomonocytic leukemia (CMML) will be presented in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting. In this Phas...

 PRESS RELEASE

Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conf...

Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti’s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025. Details of the presentation can be found below. Presenter: Mark Erlander, PhD (CEO) Date: 12/11/2025Time: 4:00 PM ET Interested pa...

Sensient Technologies Corp: 1 director

A director at Sensient Technologies Corp sold 4,518 shares at 94.809USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch